---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095417"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:04:42.320621+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Q2 net loss $9.2M; cash $69.7M; MDD collaboration with HMNC

## Summary
- Net loss $9.2M for Q2 2024 vs $12.8M in Q2 2023; operating expenses down to $11.6M.
- Cash $69.7M as of June 30, 2024, expected to fund operations through end of 2025.
- Entered collaboration with HMNC to develop tildacerfont for major depressive disorder; HMNC funds Phase 2 study.
- Topline data from CAHmelia-204 and CAHptain-205 trials expected in Q4 2024.
- Collaboration revenue $1.6M from Kaken agreement, down from $2.2M in Q2 2023.

## SEC filing metadata
- accession: 0000950170-24-095417
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017024095417/0000950170-24-095417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017024095417/sprb-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095417
- JSON: https://secwatch.observer/filing/0000950170-24-095417.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095417.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.